- Open Access
Is the exposure to bisphosphonates or osteoporosis the predictor of spinal radiographic progression in ankylosing spondylitis?
Arthritis Research & Therapy volume 20, Article number: 233 (2018)
The Correction to this article has been published in Arthritis Research & Therapy 2018 20:248
The original article was published in Arthritis Research & Therapy 2018 20:162
We read with great interest the paper by Deminger et al.  reporting determinants of radiographic progression in ankylosing spondylitis (AS). Intriguingly, the authors found bisphosphonate exposure during follow up to be a predictor of spinal radiographic progression in women. Correctly, the authors declared that their results are based on few observations and should be interpreted with caution. Indeed, it is known that the prevalence of osteoporosis, the main indication for bisphosphonate use, is high in AS patients  and associated with radiographic progression of the disease .
Unfortunately, the study presented lacks data on osteoporosis prevalence, bone mineral density, vertebral fractures, or bone turnover markers in the patients enrolled. Considering the pathophysiology of the disease, there’s rationale for a positive rather than negative effect of bisphosphonates. First, they lower bone resorption, which is known to be elevated at least in the early stages of AS. Second, suppression of bone resorption by bisphosphonates would lead, through the coupling of osteoclast and osteoblast activity, to later inhibition also of bone formation and to an increase in serum sclerostin , an inhibitor of the anabolic bone Wnt pathway and which has been described to be low in AS and negatively correlated to the development of syndesmophytes .
Although interesting, the conclusion of the authors might send an alarming message on bisphosphonate use in AS that could worsen an already low treatment rate of osteoporosis and vertebral fracture in those patients, complicating their disability. In our opinion the hypothesis that the association observed was due to more severe bone loss in those patients who show radiographic progression and that leads to the use of bisphosphonates should be considered and further investigated.
Deminger A, Klingberg E, Geijer M, Gothlin J, Hedberg M, Rehnberg E, et al. A five-year prospective study of spinal radiographic progression and its predictors in men and women with ankylosing spondylitis. Arthritis Res Ther. 2018;20(1):162.
van der Weijden MA, Claushuis TA, Nazari T, Lems WF, Dijkmans BA, van der Horst-Bruinsma IE. High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review. Clin Rheumatol. 2012;31(11):1529–35.
Klingberg E, Lorentzon M, Mellstrom D, Geijer M, Gothlin J, Hilme E, et al. Osteoporosis in ankylosing spondylitis - prevalence, risk factors and methods of assessment. Arthritis Res Ther. 2012;14(3):R108.
Gatti D, Viapiana O, Adami S, Idolazzi L, Fracassi E, Rossini M. Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone. 2012;50(3):739–42.
Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2009;60(11):3257–62.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The original version of this article was revised: Following publication of the original article, the authors reported an error. The author’s given names and family names had been transposed.
About this article
Cite this article
Orsolini, G., Adami, G., Rossini, M. et al. Is the exposure to bisphosphonates or osteoporosis the predictor of spinal radiographic progression in ankylosing spondylitis?. Arthritis Res Ther 20, 233 (2018). https://doi.org/10.1186/s13075-018-1730-9